Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

continue to focus our efforts on preparing for a successful transition to a clinical-stage company and remain on track to nominate our second microRNA candidate for clinical development by the end of the year.  Our recent progress is encouraging and we look forward to realizing the potential that our microRNA technology may have in transforming the field of drug discovery."

Neil W. Gibson , Ph.D., Chief Scientific Officer, added, "We believe that RG-101 is a novel, pan-genotypic agent that may play an important role in future HCV therapy. We are very encouraged by the pre-clinical data seen to date, which includes activity against some of the known mutations that lead to resistance to the current HCV therapies and a favorable potency and PK profile which supports a once-a-month dosing paradigm.  We believe that RG-101 may be useful in difficult-to-treat HCV patients in combination with existing and emerging therapies and we look forward to exploring its clinical utility."

Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President of Finance, said, "As we prepare for clinical activity with RG-101, Regulus continues to maintain a strong financial position with over $90 million in cash at quarter-end. We remain on track to achieve our stated goals of finishing 2013 with at least $60 million in cash, while maintaining a burn rate of approximately $30 million to $35 million."

Recent Highlight

  • Selected New Opportunity in Oncology.  Regulus also announced today that it has selected microRNA-221 (miR-221) as an attractive target for potential clinical evaluation in patients with hepatocellular carcinoma (HCC).  Regulus is currently conducting target validation activities and expects to report further progress on this opportunity in the second half of 2013.
  • First Quarter 2013 Financial Results & Highlights Regulus reported a net loss o
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    3. Regulus to Present at Future Leaders in the Biotech Industry Conference
    4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    7. Regulus to Present at Two Upcoming Investor Conferences
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... SAN DIEGO , July 30, 2015  Arena ... will host a conference call and webcast at 5:00 ... August 5, 2015, to discuss second quarter 2015 financial ... its financial results after the NASDAQ Global Select Market ... be accessed by dialing 877.643.7155 for domestic callers and ...
    (Date:7/30/2015)... EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 6, 2015, at 11:00 AM Eastern Time to ... 30, 2015, and to provide an update on the ... the Maestro® System. Conference Call Details ...
    (Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... diagnostics market 2015 research reports analyzing tumor ... well as providing forecasts for the global ... The Global Cancer Diagnostics Industry (Tumor Biomarker ... spread across 207 pages, talking about 9 ...
    Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6
    ...  MedAssurant, Inc., a leading provider of data-driven ... IPA (HCPIPA), one of the largest physician-owned ... has selected MedAssurant,s Prospective Advantage® and Capitated ... gaps in care and quality to improve ...
    ... knowing how to take a child,s temperature the correct way ... accuracy of results can be a guessing game.  The new ... Behind Ear Thermometer ... confidence to parents and peace of mind.  Using patented technology, ...
    Cached Medicine Technology:Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3Behind The Ear -- A New Site To Measure for Fever 2Behind The Ear -- A New Site To Measure for Fever 3
    (Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
    (Date:7/30/2015)... , ... July 30, 2015 , ... ... program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth ... 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 in ...
    (Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
    (Date:7/30/2015)... ... July 30, 2015 , ... ... announce its position as one of Medicare’s top-rated care centers. The video ... the CMS rating system, which monitors health inspections, staffing, and quality measures. ...
    (Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive roster ... Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that ... and marketing groups will help spread the news about the center’s leading-edge cancer ...
    Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
    ... ANN ARBOR, Mich. Having an egg allergy is ... vaccination. According to new recommendations by the American ... a history of suspected egg allergy should first be ... and diagnosis but can probably receive the vaccination. Matthew ...
    ... News) -- Very young children are extraordinarily trusting of what ... the contrary, finds a new study. In what may ... found that 3-year-olds placed more trust in information they are ... this study, an adult showed children a red and a ...
    ... Cancer Institute has awarded a $4.37 million grant to ... Center, to advance a recent scientific laboratory discovery into ... issued under the American Recovery and Reinvestment Act, will ... identified by Toretsky and his team a critical ...
    ... Texas, October 18, 2010 Estimates of the prevalence ... States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD ... function tests in the United States, a trend related ... (NASH), the progressive form of NAFLD, can lead to ...
    ... Research exploring the progression of colon polyps to ... was among the clinical science presented at the 75th ... in San Antonio today. The Progression to Colorectal ... colon known as sessile serrated adenomas (SSA) are found ...
    ... are reimbursed by Medicaid for administering influenza shots may ... the conclusion of a study published online today in ... by a team of researchers at the University of ... three flu seasons and contends that the number of ...
    Cached Medicine News:Health News:Egg allergy: Not a reason to avoid flu vaccine after all 2Health News:Egg allergy: Not a reason to avoid flu vaccine after all 3Health News:Young Kids Easily Trust What They're Told: Study 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 3Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 2Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 3Health News:Colonoscopy technique increases polyp detection in far reaches of right colon 2Health News:Medicaid reimbursement and childhood flu vaccination rates linked 2Health News:Medicaid reimbursement and childhood flu vaccination rates linked 3
    ... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
    ... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
    ... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
    ... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
    Medicine Products: